I-NEW YORK - I-Immunocore ithe ngoMsombuluko izothengisa amasheya angu-3,733,333 esivumelwaneni sezimali esizimele (PIPE) okulindeleke ukuthi siqoqe amaRandi ayizigidi ezingu-140.
Ngaphansi kwesivumelwano, i-Immunocore izothengisa isitoko sayo esivamile kanye nesitoko esivamile esingavoti ngama- $37.50 ngesabelo ngasinye. Abatshalizimali abakhona benkampani ababambe iqhaza ekuxhaseni ngezimali bahlanganisa i-RTW Investments, i-Rock Springs Capital kanye ne-General Atlantic.Isivumelwano se-PIPE kulindeleke ukuthi siphele ngoJulayi 20.
Le nkampani izosebenzisa imali ezuziwe ukuze ixhase abangenele ukhetho lwe-oncology kanye nezifo ezithathelanayo, okuhlanganisa nokuthuthukiswa kwekhandidethi eliholayo le-oncology, uKimmtrak (tebentafusp-tebn), ukwelapha i-HLA-A*02:01 isikhumba esihle kanye ne-uveal melanoma. Uxhaso, kanye nenzuzo evela ku-Kimmtrak, kulindeleke ukuthi kuxhaswe imisebenzi ye-Immunocore2025.
Kulo nyaka, uKimmtrak ugunyazwe ukusetshenziswa ezigulini ezine-HLA-A*02:01 positive unrecuble or metastatic uveal melanoma e-US, Europe nase-UK, phakathi kwamanye amazwe.I-Immunocore iyaqhubeka nokutadisha umuthi ocwaningweni lweSigaba I/II ku-HLA-A*02:01-positive cutaneous melanoma.
I-Immunocore iphinde ithuthukise amanye amakhandidethi amane e-oncology, okuhlanganisa nezidakamizwa ezimbili ezengeziwe ze-T-cell receptor ezivivinyweni zeSigaba I/II kumathumba aqinile athuthukile.Eyodwa yemithi yenzelwe i-HLA-A*02:01-positive kanye neziguli ezine-MAGE-A4-positive, kanti ezinye ezihlosiwe i-HLA-A*02:01 kanye ne-PRAME-positive enezimila ezingavalwanga enkampanini futhi zinezimila ezingavaliwe enkampanini.
Inqubomgomo Yemfihlo.imigomo Nemibandela.Copyright © 2022 GenomeWeb, iyunithi yebhizinisi ye-Crain Communications.wonke amalungelo agodliwe.